OWL Oncology Research
Jon Melton has a diverse work experience spanning over 20 years. Jon started their career with Willis as an Account Handler in 2000 and worked there until 2003. Jon then joined Marsh as an Account Executive - Assistant Vice President from 2004 to 2005. In 2006, they moved to Aon Benfield where they worked as a Reinsurance Broker for over 11 years. In 2013, they co-founded Momentum Pharma Ltd and served as the COO. In 2015, they joined OWL Oncology Research as the UK & EU Managing Director. Most recently, in 2023, they co-founded airclinical.
Jon Melton attended the University of East Anglia from 1996 to 2000, where they earned a Bachelor's Degree in Business and Financial Services.
This person is not in any teams
This person is not in any offices
OWL Oncology Research
OWL Oncology Research®, a Functional Service Provider (FSP), is a global network of hundreds of experienced clinical research experts specializing in oncology and rare disease trial monitoring, management, consulting and oversight. We deliver the highest quality clinical trial services to the pharmaceutical and biotechnology industries. Our commitment is to ensure that your clinical trials are conducted effectively and efficiently so that new and promising treatments become available to the millions of people battling these diseases. We are committed to facilitating the growing development needs of biotechnology companies in a world where increasingly, large conglomerated contract research organizations (CRO) are defining industry standards for clinical research. These CRO-defined "standards" are often excessive, or even at odds with current regulatory and international guidance, resulting in tangential focus, misleading project scopes, and unnecessary costs. It is our standard and privilege to ensure that new, promising oncology therapeutics are granted the attention, respect, and experienced teams that they deserve, without the cost or intimidation of a large CRO.